BioPharma Dive June 7, 2024
A vote against MDMA-assisted therapy set back a high-profile treatment. Proponents argue FDA advisers offered few solutions to longstanding problems.
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained momentum over the last several years. But some proponents believe that progress was undercut this week, when one of the field’s most advanced therapies hit a significant setback.
On Tuesday, the Food and Drug Administration convened a group of outside advisers to assess whether a company named Lykos Therapeutics had gathered enough evidence to show MDMA — better known to some as the party drug ecstasy — is an effective therapy aid for people with post-traumatic stress disorder.
A positive...
Today's Sponsors
Today's Sponsor